Israeli biotech startup Immunai announced on Wednesday that it has raised a $215 million Series B at a valuation of just over $1 billion. Immunai, which uses single-cell genomics and machine learning to discover and develop novel therapeutics that reprogram the immune system, has raised $295 million to date, completing a $60 million Series A just eight months ago. The Series B was led by Koch Disruptive Technologies, with participation from Talos VC, 8VC, Alexandria Venture Investments, Piedmont, ICON, and more, including previous investors.

“We have developed a platform that analyzes and maps the immune system with very advanced single-cell genomic methods and artificial intelligence,” Noam Solomon, Ph.D., CEO and co-founder of Immunai, told Calcalist. “Humanity celebrated 20 years ago the mapping of the human genome and we have mapped the entire immune system with millions of cells that are connected to one another. This has resulted in a bank of cells in different states of health and disease. Our technology shows what happens to our immune system and provides insights that allow us to develop new medicine and treatments.